The genetic basis of severe hypofibrinogenemia was analyzed in a 57-year-old Italian woman. She turned out to be a compound heterozygote for a novel putative missense mutation (Leu172Gln) and a previously described nonsense mutation (Arg17ter) 
ABSTRACT
The genetic basis of severe hypofibrinogenemia was analyzed in a 57-year-old Italian woman. She turned out to be a compound heterozygote for a novel putative missense mutation (Leu172Gln) and a previously described nonsense mutation (Arg17ter) 6 The genetic basis of these rare coagulation disorders are invariantly represented by mutations within the fibrinogen genes.
7
In this study, we analyzed the genetic defects underlying severe hypofibrinogenemia in a proband originally described in 1972. 8 The patient was found to be a compound heterozygote for a previously reported nonsense mutation and a novel missense mutation. The latter was demonstrated to exert its pathogenetic effect at the mRNA processing level by activating a cryptic acceptor splice site.
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STUDY DESIGN

Case report and laboratory measurements
The patient is a 57-year-old Italian woman with consistently moderate hemorrhagic symptoms. Plasma fibrinogen concentration was re-evaluated by a functional assay based on fibrin polymerization time 9 and by an enzyme-linked immunosorbent assay (ELISA). 10 Resulting levels (10 mg/dL and 14.1 mg/dL for functional and immunoreactive fibrinogen, respectively; normal range for both tests: 160-400 mg/dL) were concordant with previous data, 8 confirming the diagnosis of severe hypofibrinogenemia.
DNA extraction, sequence analysis, in-vitro mutagenesis and cloning of Polymerase Chain
Reaction (PCR) products
The patient signed an informed consent according to the Declaration of Helsinki. All procedures were performed as described.
11
Protein analysis
Expression of wild-type and mutant fibrinogen was achieved by transiently co-transfecting COS-1 cells with plasmids containing the cDNAs for the 3 fibrinogen chains, as described.
12
Pulse-chase experiments, immunoprecipitations, sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), and evaluation of fibrinogen antigen levels in conditioned media and cell lysates by ELISA were performed as described. 
RESULTS AND DISCUSSION
DNA sequencing of the fibrinogen cluster revealed the patient to be a compound heterozygote for 2 point mutations in FGB. One was a novel T>A transversion in exon 4 at position 5157 (numbering according to GenBank M64983), predicted to cause the Leu172Gln substitution (numbering omits the signal peptide). The other mutation was a C>T transition at position 3282 in exon 2, causing a nonsense mutation at residue 17. This mutation (Arg17ter) was previously reported in the homozygous state in an Iranian afibrinogenemic patient. 14 Although the Leu172Gln substitution is nonconservative (hydrophobic to polar), its impact on fibrinogen assembly and folding is uncertain since the side chain of Gln172 is comparable with that of the wild type Leu172 and therefore could fit into the hydrophobic core of the coiled coil region of fibrinogen.
To confirm the causal role of Leu172Gln in-vitro expression experiments were performed by transiently co-expressing the mutant B protein with the wild-type A -and -chains in COS-1 cells, not-expressing fibrinogen ( Figure 1A and B). The 340-kDa fibrinogen band, corresponding to the hexameric molecule, was detectable in both wild-type and mutant samples as well as in control fibrinogen-expressing HepG2 cells, whereas it was absent in mock-transfected cells. These data (confirmed by densitometric quantitation of fibrinogen bands, Figure 1A and B, right panel) demonstrated a normal intracellular assembly and secretion of B -Leu172Gln fibrinogen. Fibrinogen levels in both conditioned media and lysates of cells transfected with the mutant plasmid were also evaluated by ELISA and resulted even slightly higher than those measured in wild-type samples ( Figure 1C ), thus convincingly confirming that Leu172Gln does not interfere with fibrinogen synthesis, intracellular processing, and secretion. Even though Leu172Gln had no apparent effect at the protein level, it still remained a good candidate as causative mutation. Actually, no other putative pathogenetic mutation was found in the sequenced regions of the fibrinogen cluster and the sole presence of Arg17ter in the proband was not sufficient to account for severe hypofibrinogenemia. In fact, this same mutation was previously reported to be associated with mildly reduced fibrinogen levels in both heterozygous parents of an Iranian afibrinogenemic patient. To test whether Leu172Gln (hereafter referred to as 5157T>A) was itself a splicing mutation, part of the B transcript (either wild type or containing 5157T>A) was produced in HeLa cells by transient transfection with 2 minigene constructs (pT-B -In2/In5-5157T>A and pT-B -In2/In5-wt) (see Study Design and Figure 2A ). RT-PCR on total RNA from cells transfected with pT-B -In2/In5-5157T>A gave rise to a major product (shorter than expected) ( Figure 2B ) and a minor 466-bp product corresponding to the wild-type one, suggesting low levels of residual wild-type splicing. Sequencing revealed that the shorter fragment (350 bp) resulted from the use of a cryptic acceptor splice site generated by the 5157T>A mutation ( Figure 2B ). This would result in a frameshift and a premature stop at residue 146 of the mutant protein, preceded by a scrambled sequence of 12 residues. Therefore 5157T>A represents the first exonic splicing mutation identified so far in the fibrinogen genes. An about 10% residual wild-type splicing was calculated by the fluorescent hot-stop PCR technique 11 ( Figure 2C ). Assuming that this result does mimic the in-vivo situation, it might explain the low but measurable level of immunoreactive fibrinogen in the proband's plasma.
These findings strengthen the concept that no safe prediction of phenotypes of mutations is feasible until an accurate functional analysis at the protein and/or RNA level has been performed.
